Fertility device and equipment companies advanced through AI-enabled lab automation, imaging innovation, robotic workflow tools, clinical research, and international commercialization
AI-assisted systems became more visible in both laboratory and imaging environments, with companies applying computer vision, machine learning, robotics, and workflow automation to sperm selection, IVF lab processes, ultrasound, and fertility monitoring. Device companies also emphasized clinical validation, regulatory milestones, and research visibility as fertility providers weighed new technologies against the operational realities of embryology labs and reproductive medicine practices.
The category also reflects broader fertility industry priorities: increasing clinic throughput, reducing operator variability, improving patient access, supporting international expansion, and standardizing complex procedures. In some cases, automation is being positioned as a way to address bottlenecks in embryology and IVF lab capacity. In others, imaging and wearable technologies are extending fertility-related insights beyond the clinic and into broader women’s health and reproductive monitoring.
BAIBYS Fertility reports first pregnancy from automated ICSI
A notable milestone came in April 2026 when BAIBYS reported the first pregnancy achieved using its autonomous AI-based robotic sperm-selection system. The development represents an early clinical milestone for the company’s technology and reflects broader industry efforts to apply automation and machine learning to laboratory procedures that have traditionally relied on highly specialized manual expertise
The company also strengthened its intellectual-property position during the period. In 2026, BAIBYS announced that it had received a USPTO Notice of Allowance for an AI-powered sperm-analysis patent covering technology used to identify and evaluate sperm cells through artificial-intelligence models. The milestone adds to the company’s growing portfolio of technology assets supporting automated sperm assessment and selection.
Industry recognition followed as BAIBYS received the Most Innovative Device award among life-science startups at Biomed Israel 2026. While awards do not establish clinical outcomes, the recognition reflects growing visibility for AI-enabled fertility devices and highlights continued interest in automation technologies designed for embryology and IVF laboratories.
Clinical research also remained central to the company’s development strategy. BAIBYS continued a prospective clinical study evaluating its sperm-selection system against conventional manual sperm selection during ICSI, with outcomes including embryo quality, implantation rates, and live-birth results.
Conceivable Life Sciences Proves Automated IVF Concept
In September 2025, Conceivable secured a $50 million Series A financing round led by Advance Venture Partners, with participation from ARTIS Ventures, Stride, and ACME. The company stated that the capital would support development and commercialization of its AI-powered automated IVF laboratory, U.S. expansion, and manufacturing scale-up (BioSpace, GlobeNewswire). AlleyWatch included the financing among the largest New York startup funding rounds announced in September 2025.
The company’s AURA platform is designed to automate complex IVF lab processes by combining robotics, computer vision, advanced optics, and machine-learning systems. Conceivable describes the platform as capable of supporting workflow steps across gamete preparation, sperm selection, ICSI, embryo culture, and vitrification
Clinical studies published by Conceivable and its collaborators have examined automated approaches to gamete preparation, ICSI, embryo culture, and vitrification, supporting the company’s broader effort to develop an automated IVF laboratory platform.
In 2025, researchers associated with Conceivable reported a proof-of-concept study in Human Reproduction demonstrating the use of automated systems across multiple Day 0 IVF laboratory procedures, including sperm preparation, oocyte handling, and ICSI. The study resulted in fertilization, embryo development, pregnancies, and five healthy live births, providing early clinical evidence that automation can be incorporated into IVF laboratory workflows while supporting viable embryo development and successful pregnancy outcomes.
Samsung
Samsung emphasized AI-supported ultrasound innovation through women’s health imaging. In 2025, Samsung showcased life-cycle ultrasound solutions at ISUOG, including systems designed to support women’s health imaging across reproductive and obstetric care.
Samsung also highlighted the HERA Z20 platform, which incorporates AI-enabled tools designed to automate image acquisition, support anatomical measurements, and improve workflow efficiency for clinicians across fertility, gynecologic, and obstetric imaging. Samsung Healthcare USA also introduced the R20 ultrasound system, highlighting AI-enabled imaging capabilities, workflow improvements, and advanced diagnostic tools intended to support clinician efficiency.
Was Your Org Not Included?
Don't let your company miss out again.
Your company may have missed out on this coverage of your category before ESHRE, but Inside Reproductive Health overviews your category 4x per year.
Your competitors were covered because they are IVF Heroes Universe sponsors.
Don't miss out on the next coverage of your category--released before ASRM.
Over 60 leading fertility companies are leaders in the IVF Heroes Universe, isn't yours?
Year-long sponsorship is only $2,295 for the entire year, but get in now, before prices go up.